5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer | Zendy

Mark Preston | Zendy; Kathryn M. Wilson | Zendy; Sarah C. Markt | Zendy; Rongbin Ge | Zendy; Christopher Morash | Zendy; Meir J. Stampfer | Zendy; Massimo Loda | Zendy; Edward L. Giovannucci | Zendy; Lorelei A. Mucci | Zendy; Aria F. Olumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer

Author(s) -

Mark Preston,

Kathryn M. Wilson,

Sarah C. Markt,

Rongbin Ge,

Christopher Morash,

Meir J. Stampfer,

Massimo Loda,

Edward L. Giovannucci,

Lorelei A. Mucci,

Aria F. Olumi

Publication year - 2014

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2014.1600

Subject(s) - medicine , prostate cancer , dutasteride , hazard ratio , prostate , 5 alpha reductase inhibitor , cancer , proportional hazards model , confounding , oncology , finasteride , gynecology , urology , confidence interval

5α-Reductase inhibitors (5ARIs) are widely used for benign prostatic hyperplasia despite controversy regarding potential risk of high-grade prostate cancer with use. Furthermore, the effect of 5ARIs on progression and prostate cancer death remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research